Advertisement

Topics

Ovid Therapeutics Inc. Company Profile

13:45 EDT 18th June 2018 | BioPortfolio

Ovid Therapeutics Inc. is a privately-held, New York based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain and few, if any, treatment options - patients who currently have no hope of cure or improvement. Ovid focuses on patients and their needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline coupled with compelling research and development.


News Articles [804 Associated News Articles listed on BioPortfolio]

Ovid Therapeutics (OVID) - Analysts' Recent Ratings Changes

According to Zacks, "Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders.

Ovid Therapeutics (OVID) Cut to "Hold" at Zacks Investment Research

According to Zacks, "Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders.

Ovid Therapeutics (OVID) Stock Rating Lowered by Zacks Investment Research

According to Zacks, "Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders.

Ovid Therapeutics (OVID) Presents At Jefferies 2018 Global Healthcare Conference - Slideshow

Ovid Therapeutics (OVID) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow

Ovid Therapeutics (OVID) Presents At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference - Slideshow

Will Butterflies Or Moths Emerge From Ovid's Cocoons?

"In the make-up of human beings, intelligence counts for more than our hands, and that is our true strength." Ovid Therapeutics is a young biopharmaceutical company that was founded in 2014 and went p...

Recent Research Analysts' Ratings Updates for Ovid Therapeutics

They set a "buy" rating and a $20.00 price target on the stock. 5/10/2018 - Ovid Therapeutics was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating.

PubMed Articles [435 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Survivor Notification of Post-Disaster Mental Health Services: An Integrative Review.

This integrative review identifies notification methods for psychiatric mental health services for adult survivors of natural disasters for articles published from 2011 through 2016. Databases searche...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Clinical Trials [147 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1239 Associated Companies listed on BioPortfolio]

Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a privately-held, New York based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain an...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Ovid Therapeutics Inc." on BioPortfolio

We have published hundreds of Ovid Therapeutics Inc. news stories on BioPortfolio along with dozens of Ovid Therapeutics Inc. Clinical Trials and PubMed Articles about Ovid Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ovid Therapeutics Inc. Companies in our database. You can also find out about relevant Ovid Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Corporate Database Quicklinks



Searches Linking to this Company Record